Among all CGA candidates, melanoma-associated antigen A3 (MAGE-A3), New York esophageal squamous cell carcinoma-1 (NY-ESO-1) antigen, and preferentially expressed antigen in melanoma (PRAME) have been well-studied and proved to be promising cancer vaccine targets. This evidence concerns the gene MAGEA3 and cancer.